Advanced Bionics announces FDA approval of Naída CI Q90 and Q30

CI

Advanced Bionics, subsidiary of Sonova Holding AG, has received FDA approval in the United States for its new Naída CI Q90 and Q30 sound processors. FDA approval follows Health Canada approval earlier this year. Distribution of the Naída CI Q90 sound processor is expected later this year in the United States and Canada.

Commenting on the approval, Lukas Braunschweiler, CEO of Sonova said: “Building on the unique innovations introduced with the Naída CI Q70 sound processor in 2013, the new Naída CI Q90 and Q30 processors are further evidence of our clear commitment to be customer driven, bringing together the innovation DNA of Advances Bionics and Phonak. The new devices deliver on our promise to innovate, differentiate and provide our customers with the most comprehensive range of products in the industry. I am confident that this launch will further support the long-term, sustainable growth of Sonova’s implant business.”

Source: Sonova Holding AG